MYDAYIS

Phase 3Small molecule

MMayo Clinic

MYDAYIS is one of 13 small molecule programs targeting Executive Function. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Executive FunctionActive, not recruiting

Executive FunctionPhase 3

Active, not recruiting

Competition

Competitive Landscape

16 competitors in Executive Function

#DrugCompanyPhaseTrials

Ritalin

Novartis

Approved

2 2

Azilect

Teva

Approved

1 3

Vyvanse

Takeda

Approved

1 4

Strattera

MMap77

Approved

1 5

Intuniv

PPromius Pharma, LLC

Approved

1 6

Tasmar

BBausch Health Americas, Inc.

Approved

—7

Methylphenidate Hydrochloride

Takeda

Approved

1 8

SPD489

Takeda

Approved

1 9

Stimulant Therapy

Otsuka

Approved

1 10

MYDAYIS

MMayo Clinic

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Executive Function1 trial

Study of the Duration and Efficacy of MYDAYIS on Adult ADHD Symptoms and Executive Function Throughout the Day Into the Early Evening

Completed·NNYU Langone Health·Phase 3·NCT03945175·52 enrolled

Bipolar Depression1 trial

8 Week Multi-site Study of MYDAYIS® for Bipolar Depression

Completed·MMayo Clinic·Phase 2·NCT04235686·74 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for MYDAYIS. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — MYDAYIS compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for MYDAYIS. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Mayo Clinic company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: MMayo Clinic

MYDAYIS

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Executive Function1 trial

Bipolar Depression1 trial

References

Drug Info

Quick Facts

Related News